This is a preview of subscription content, log in via an institution to check access.
References
Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., et al., ed. (2017). AJCC Cancer Staging Manual. 8th ed. (Springer).
Aysola, K., Desai, A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech, D.J., et al. (2013). Triple negative breast cancer—an overview. Hereditary Genets 2013, 001.
Bidard, F.C., Proudhon, C., and Pierga, J.Y. (2016). Circulating tumor cells in breast cancer. Mol Oncol 10, 418–430.
Brabletz, T. (2012). To differentiate or not—routes towards metastasis. Nat Rev Cancer 12, 425–436.
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20, 806–815.
Jiang, Z., Yan, M., Hu, X., Zhang, Q., Ouyang, Q., Feng, J., Yin, Y., Sun, T., Tong, Z., Wang, X., et al. (2019). Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. JCO 37, 1001
Li, X., Yang, J., Peng, L., Sahin, A.A., Huo, L., Ward, K.C., O’Regan, R., Torres, M.A., and Meisel, J.L. (2017). Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161, 279–287.
Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., Li, H., Yu, S., Feng, J., Wang, S., et al. (2019). Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol 37, 2610–2619.
Martin, M., Holmes, F.A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S.K.L., Mansi, J., Barrios, C.H., et al. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 18, 1688–1700.
Masuda, N., Lee, S.J., Ohtani, S., Im, Y.H., Lee, E.S., Yokota, I., Kuroi, K., Im, S.A., Park, B.W., Kim, S.B., et al. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376, 2147–2159.
Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., Diéras, V., Hegg, R., Im, S.A., Shaw Wright, G., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379, 2108–2121.
Somashekhar, S.P., Sepúlveda, M.J., Puglielli, S., Norden, A.D., Shortliffe, E.H., Rohit Kumar, C., Rauthan, A., Arun Kumar, N., Patil, P., Rhee, K., et al. (2018). Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol 29, 418–423.
von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380, 617–628.
Yang, Y., Liu, J., Peng, M., Su, F., Xie, X., Liu, Z., Wu, J., Wei, W., Zhou, D., Li, W., et al. (2020). Introduction of a multicenter online database for non-metastatic breast cancer in China. Sci China Life Sci https://doi.org/10.1007/s11427-019-1625-1.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Li, Q., Liu, J., Jiang, Z. et al. CSCO breast cancer guideline: precise, economical and oriental. Sci. China Life Sci. 63, 1410–1412 (2020). https://doi.org/10.1007/s11427-020-1701-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-020-1701-5